How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,307 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation

Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study (...) Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov

2013 Clinical Trials

182. A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management. (PubMed)

these parameters for a nonhuman primate exposed to total body radiation and administered medical management. A blinded, randomized study (n = 48 rhesus macaques) determined the lethal dose-response relationship using bilateral 6 MV linear accelerator photon radiation to doses in the range of 7.20 to 8.90 Gy at 0.80 Gy min(-1). Following irradiation, animals were monitored for complete bloodcounts, body weight, temperature, diarrhea, and hydration status for 60 d. Animals were administered medical management (...) consisting of intravenous fluids, prophylactic antibiotics, blood transfusions, anti-diarrheals, analgesics, and nutrition. The primary endpoint was survival at 60 d post-irradiation; secondary endpoints included hematopoietic-related parameters, number of transfusions, incidence of documented infection, febrile neutropenia, severity of diarrhea, mean survival time of decedents, and tissue histology. The study defined an LD30/60 of 7.06 Gy, LD50/60 of 7.52 Gy, and an LD70/60 of 7.99 Gy with a relatively

Full Text available with Trip Pro

2012 Health physics

183. A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications

A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional Medications The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01600521 Recruitment Status : Completed First Posted : May 17, 2012 Last Update Posted : April

2012 Clinical Trials

184. A Study in Healthy Volunteers to Evaluate Effects of Pre-Medication or Slow Dose Titration on Flushing and Gastrointestinal Events

, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration. Secondary Outcome Measures : Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious AEs (SAEs) [ Time Frame: Day 1 up to end of Safety Follow-up (9 weeks) ] AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose (...) A Study in Healthy Volunteers to Evaluate Effects of Pre-Medication or Slow Dose Titration on Flushing and Gastrointestinal Events Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2012 Clinical Trials

185. Educational-Medical-Behavioral Treatment of Fecal Incontinence

to be effective in single-site studies will sustain its efficacy when disseminated to a home bound population by home health care nurses. The treatment includes patient education about the physiology of how continence is maintained, pelvic floor exercises, behavioral strategies for preventing FI, and use of fiber or nonprescription medication to treat diarrhea or constipation. To minimize drift when the treatment is disseminated to a large group of providers, patient education and other basic components (...) Educational-Medical-Behavioral Treatment of Fecal Incontinence Educational-Medical-Behavioral Treatment of Fecal Incontinence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Educational-Medical-Behavioral

2012 Clinical Trials

186. A cross-sectional study of the association between overnight call and irritable bowel syndrome in medical students (PubMed)

A cross-sectional study of the association between overnight call and irritable bowel syndrome in medical students Shift work has been associated with irritable bowel syndrome (IBS), which includes gastrointestinal symptoms such as abdominal pain, constipation and diarrhea. Overnight call shifts also lead to a disruption of the endogenous circadian rhythm.Medical students who perform intermittent overnight call shifts will demonstrate a higher prevalence of IBS symptoms when compared (...) measure (IBS-QOL). The prevalence of IBS symptoms and quality of life secondary to those symptoms were determined.Data were available for 247 medical students (110 preclinical students, 118 clerkship students and 19 excluded surveys). There was no significant difference in the presence of IBS between preclinical and clerkship students (21 of 110 [19.1%] versus 26 of 118 [22.0%]; P=0.58). The were no significant differences in mean (± SD) IBS-QOL score of those with IBS between preclinical (43.5±8.3

Full Text available with Trip Pro

2012 Canadian Journal of Gastroenterology

187. Managing Medication-induced Constipation in Cancer: A Clinical Trial

an eight week period and to evaluate the relationship between constipation intensity and vinca alkaloid dose. Secondary Outcome Measures : Phase II - Number of Participants With Desired Effect - Patients with Medication-induced Constipation [ Time Frame: 2 years, 3 months ] To test the efficacy of a Constipation Treatment Protocol in patients with medication-induced constipation. Phase II - Best Determination of Laxative Dose - Patients with Medication-induced Constipation [ Time Frame: 2 years, 3 (...) Managing Medication-induced Constipation in Cancer: A Clinical Trial Managing Medication-induced Constipation in Cancer: A Clinical Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Managing Medication

2011 Clinical Trials

188. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. (ADHERE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2011 Clinical Trials

189. Patients Hospitalized with pH1N1 Influenza in an Academic Community Medical Center (PubMed)

consecutive patients that were admitted to our hospital with a primary or secondary diagnosis of influenza from October 1-November 30, 2009. Data were obtained through care of the patients and chart review.Prominent symptoms on admission included fever, hypoxia, cough, myalgias, and diarrhea, with leukocytosis and neutrophilia. Pre-existing medical conditions included asthma, pregnancy, immunosuppressive therapy, and sickle cell disease. All but 5 of the patients were under 60 years of age. Three patients (...) Patients Hospitalized with pH1N1 Influenza in an Academic Community Medical Center The emergence of a novel strain of pandemic influenza (pH1N1) in 2009 presented significant challenges to health care facilities worldwide. In our academic community medical center in suburban Philadelphia, we noted our first pH1N1 diagnosis in September 2009. We sought to assess the impact of pH1N1 disease on our hospitalized patient population.We prospectively collected clinical and epidemiological data on 29

Full Text available with Trip Pro

2011 The open respiratory medicine journal

190. Secondary Erythrocytosis

Secondary Erythrocytosis Secondary Erythrocytosis - Hematology and Oncology - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Multiple (...) of ADP Receptor ADP receptors are integral proteins embedded in a platelet membrane. When ADP binds, it causes a conformational change in the fibrinogen receptor, which allows fibrinogen to bind to the receptors... SOCIAL MEDIA Add to Any Platform Loading , MD, James P. Wilmot Cancer Institute, University of Rochester Medical Center; , MD, University of Rochester Medical Center Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Secondary erythrocytosis

2013 Merck Manual (19th Edition)

191. Secondary Adrenal Insufficiency

Secondary Adrenal Insufficiency Secondary Adrenal Insufficiency - Endocrine and Metabolic Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test (...) Endocrine System Video Overview of Buffering and the Henderson-Hasselbalch Equation SOCIAL MEDIA Add to Any Platform Loading , MD, University of Oxford; Fellow, Green-Templeton College Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Topic Resources Secondary adrenal insufficiency is adrenal hypofunction due to a lack of adrenocorticotropic hormone (ACTH). Symptoms are the same as for and include fatigue, weakness, weight loss, nausea, vomiting, and diarrhea

2013 Merck Manual (19th Edition)

192. Secondary Iron Overload

Secondary Iron Overload Secondary Iron Overload - Hematology and Oncology - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Multiple (...) Biopsy SOCIAL MEDIA Add to Any Platform Loading , MD, Johns Hopkins University School of Medicine Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Secondary iron overload results from excess absorption of iron, repeated blood transfusions, or excess oral intake, typically in patients with disorders of erythropoiesis. Consequences can include systemic symptoms, liver disorders, cardiomyopathy, diabetes, erectile dysfunction, and arthropathy. Diagnosis is by elevated

2013 Merck Manual (19th Edition)

193. Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria: Diarrhea or diarrhea predominant IBS patients Age 18 to 65 BDQ confirms presence of IBS-D or functional diarrhea, positive by Rome III criteria No restrictions on Hospital Anxiety Depression score No abdominal surgery (except appendectomy and cholecystectomy) Exclusion criteria: Serum tissue transglutaminase IgA or IgG positive or medical record of small bowel biopsy suggestive of celiac disease Use of tobacco (...) Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2010 Clinical Trials

194. Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

on an outpatient basis. Biological: Placebo Placebo Outcome Measures Go to Primary Outcome Measures : Severe diarrhea: ≥6 grade 3-5 stools in 24 hrs, or >800g of grade 3-5 stools in 24 hrs and moderate diarrhea: 4-5 grade 3-5 stools in 24 hrs or 401-800g of grade 3-5 stools in 24 hrs [ Time Frame: Study Day 49 to 57 ] Secondary Outcome Measures : Number of subjects with severe diarrhea (if any) [ Time Frame: Study Day 49 to 57 ] Number of subjects with diarrhea of any severity [ Time Frame: Study Day 49 to 57 (...) or more than 3 per day). Regular use of laxatives, antacids, or other agents to lower stomach acidity. Use of any medication known to affect the immune function (e.g., corticosteroids and others) within 30 days preceding the first vaccination or planned use during the active study period. Known allergy to two of the following antibiotics: quinolones, trimethoprim-sulfamethoxazole, and penicillin. Symptoms consistent with Traveler's Diarrhea concurrent with travel to countries where ETEC infection

2010 Clinical Trials

195. Efficacy and Safety of Lactobacillus Acidophilus/Rhamnosus Combination for the Prevention of Antibiotic-associated Diarrhea in the Elderly

stools in a 24 hour period. [ Time Frame: Monitored cnce daily at start of study product, then weekly x 3 weeks after last antibiotic dose ] Secondary Outcome Measures : Incidence of CDI as detected by a stool assay (detection of toxins A or B) [ Time Frame: Measured if diarrhea develops in hospital during antibiotic treatment or during the 3 weeks following last antibiotic dose ] Duration of hospital stay [ Time Frame: Day of hospital admission until day of discharge ] Incidence of adverse effects (...) Patients who have active diarrhea at enrollment Patients who have been diagnosed with CDI within the previous 3 months Patients who are lactose intolerant Patients who have an underlying chronic GI tract disease (inflammatory bowel disease, irritable bowel syndrome) Patients who have an ileostomy or colostomy Patients who regularly take probiotics Patients who are severely immunocompromised (HIV positive, transplant patient, on antirejection medications, on a steroid for >30 days, or chemotherapy

2010 Clinical Trials

196. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. (PubMed)

of 215 patients were included in the final analysis. The primary endpoint was the incidence of grade 2-4 acute diarrhea; secondary endpoints included treatment compliance, medical resource utilization, patient-reported bowel function, and quality of life (QoL). Statistical tests were one- or two-sided, as specified.After a median follow-up time of 9.64 months, incidence rates of grades 2-4 acute diarrhea were similar in both groups (49% placebo vs 44% LAO; P = .21). No statistically significant (...) treatment differences in chemotherapy or radiation delivery, medical resource utilization, patient-reported bowel function, or QoL were observed.In this study, the prophylactic use of LAO did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL.

Full Text available with Trip Pro

2010 Journal of the National Cancer Institute.

197. Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

Sponsor: Case Western Reserve University Collaborator: BioGaia AB Information provided by (Responsible Party): Alison Steiber, Case Western Reserve University Study Details Study Description Go to Brief Summary: The purpose of this study is to find whether Lactobacillus reuteri prevents antibiotic-associated diarrhea and related Clostridium difficile infections. Subjects will be admitted from the University Hospitals Case Medical Center. They will be randomly assigned to an intervention group (...) receiving L. reuteri or a placebo. Supplementation will occur during antibiotic treatment and for an additional 7 days after cessation of treatment. Data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic cessation, and 21 days after antibiotic cessation. Primary data includes diarrhea instances. Secondary data includes severity of diarrhea, presence of C. difficile toxins, and presence of other GI symptoms. Condition or disease Intervention/treatment Phase Antibiotic

2010 Clinical Trials

198. Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

Posted : December 31, 2010 Last Update Posted : July 21, 2011 Sponsor: Sprim Advanced Life Sciences Information provided by: Sprim Advanced Life Sciences Study Details Study Description Go to Brief Summary: Primary Objective: • To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and functional dyspepsia Secondary Objective (...) Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2010 Clinical Trials

199. LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

adequately to other IBS therapy will be eligible to enroll in the study. Criteria Inclusion Criteria: Be a female between 18 and 65 years of age (inclusive) at Visit 1. Sign and date a written informed consent form prior to the initiation of any study-related activities, including discontinuation of any prohibited medications. Be diagnosed with severe, diarrhea-predominant IBS. Have experienced chronic IBS symptoms lasting 6 months or longer. Have not responded adequately to other IBS therapy. Be able (...) LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LOTRONEX®

2010 Clinical Trials

200. Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

Posted : March 21, 2017 Sponsor: Forest Laboratories Information provided by (Responsible Party): Forest Laboratories Study Details Study Description Go to Brief Summary: Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea. In this study, Lacteol® 340 mg will be evaluated as a potential therapy for the treatment of diarrhea-predominant (...) irritable bowel syndrome (IBS-D). Condition or disease Intervention/treatment Phase Diarrhea-predominant Irritable Bowel Syndrome Drug: LACTEOL® 340 mg Drug: PLACEBO Phase 3 Detailed Description: This study will include the following phases: Screening Phase, Run-In Phase, Double-Blind Treatment Phase and Open-Label Treatment Phase. Screening: Eligibility of subjects will be evaluated following informed consent signature. Screening procedures/evaluations (physical exam, concomitant medications, clinical

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>